Dr Dangs Lab Conducted Lab Tests for All 3 Phases of Trial for Corbevax (COVID-19) Vaccine Launched by Biological E

NEW DELHI: Dr Dangs Lab has successfully conducted screening, safety and several immunogenicity tests for all the three phases of trial for Biological E’s Corbevax - the first indigenously developed protein-subunit vaccine against COVID-19 and the third vaccine ( after Covaxin and ZyCoV-D) to be made-in-India. Corbevax utilizes the receptor-binding domain from the spike protein as the vaccine antigen.

The timely and high quality reporting of the lab tests for the Corbevax trials - conducted at Dr DANGS LABS in New Delhi - was the result of relentless hard work by the team carried out with clockwork precision under the close watch of experts , featuring deeply orchestrated accurate lab assays, project management, tech transfers and efficient bio-repository management. Rigorous quality benchmarks, such as GCLP guidelines as mandated by regulatory authorities, were adhered to.

“We at Dr. DANGS LABS are humbled and elated to be part of this important milestone. The testing for the Corbevax trial called for close coordination with participating investigative sites, principal investigators as well as efficient handling of pan-India logistics - and the team pulled it off with characteristic efficiency. Proud to have been chosen as the central lab of choice to provide end to end services ", said Dr Arjun Dang, CEO of Dr DANGS LAB.

The development has come in the wake of the Drug Controller General of India (DCGI) approving two new Covid-19 vaccines and one anti-viral drug for emergency use on Tuesday.

Dr DANGS LAB is an NCR based premium lab chain recognized for its ethos of personalised and high quality diagnostic services. It also partners with various institutes and companies for academic research and clinical trials.

*This Press Release is published by VOH team.*